ARRY - ONTY/380 deal CC notes (5/30/13)
1. ONTY responsible for funding Phase 2 PoC trials and they will test ARRY-380 with approved breast cancer drugs. Reference during Q&A that the multiple Phase 2 PoC trials could include combo of 380 with pertuzumab, T-DM1, Herceptin, capecitabine, and the taxanes. (ARRY has not discussed with ONTY if there will be combo trials of 380 with ONTY's PI3K, PX-866.)
2. ARRY-380 is the only selective small molecule HER2 inhibitor in the clinic or on the market.
3. Some perceived advantages of 380 over other HER2 drugs include low incidence of rash/GI side effects (limiting for other HER2 drugs) and the ability to penetrate blood brain barrier and treat brain mets.
4. If ARRY opts out of Phase 3 co-development, they expect the royalty due to ARRY will be double-digit.
